 OncoSec Medical Incorporated the Company or OncoSec Nasdaq: ONCS, a company developing late-stage intratumoral cancer immunotherapies, today presented new data further demonstrating the power of OncoSecs next-generation interleukin-12 IL-12 plasmid TAVOPLUS therapeutic when combined with a T cell stimulator TAVOPLUS-CD3 or an enhanced chemokine gradient TAVOPLUS-CXCL9. These product candidates, coupled with the new low-voltage electroporation gene delivery system, represent a promising approach for treating patients with a variety of solid tumors. The data were presented today during two late-breaking poster presentations at the American Association for Cancer AACR Virtual Annual Meeting II being held from June 22-24, 2020. 